Abstract
Background There is considerable variability in COVID-19 outcomes amongst younger adults—and some of this variation may be due to genetic predisposition. We characterized the clinical implications of the major genetic risk factor for COVID-19 severity, and its age-dependent effect, using individual-level data in a large international multi-centre consortium.
Method The major common COVID-19 genetic risk factor is a chromosome 3 locus, tagged by the marker rs10490770. We combined individual level data for 13,424 COVID-19 positive patients (N=6,689 hospitalized) from 17 cohorts in nine countries to assess the association of this genetic marker with mortality, COVID-19-related complications and laboratory values. We next examined if the magnitude of these associations varied by age and were independent from known clinical COVID-19 risk factors.
Findings We found that rs10490770 risk allele carriers experienced an increased risk of all-cause mortality (hazard ratio [HR] 1·4, 95% confidence interval [CI] 1·2–1·6) and COVID-19 related mortality (HR 1·5, 95%CI 1·3–1·8). Risk allele carriers had increased odds of several COVID-19 complications: severe respiratory failure (odds ratio [OR] 2·0, 95%CI 1·6-2·6), venous thromboembolism (OR 1·7, 95%CI 1·2-2·4), and hepatic injury (OR 1·6, 95%CI 1·2-2·0). Risk allele carriers ≤ 60 years had higher odds of death or severe respiratory failure (OR 2·6, 95%CI 1·8-3·9) compared to those > 60 years OR 1·5 (95%CI 1·3-1·9, interaction p-value=0·04). Amongst individuals ≤ 60 years who died or experienced severe respiratory COVID-19 outcome, we found that 31·8% (95%CI 27·6-36·2) were risk variant carriers, compared to 13·9% (95%CI 12·6-15·2%) of those not experiencing these outcomes. Prediction of death or severe respiratory failure among those ≤ 60 years improved when including the risk allele (AUC 0·82 vs 0·84, p=0·016) and the prediction ability of rs10490770 risk allele was similar to, or better than, most established clinical risk factors.
Interpretation The major common COVID-19 risk locus on chromosome 3 is associated with increased risks of morbidity and mortality—and these are more pronounced amongst individuals ≤ 60 years. The effect on COVID-19 severity was similar to, or larger than most established risk factors, suggesting potential implications for clinical risk management.
Funding Funding was obtained by each of the participating cohorts individually.
Competing Interest Statement
JBR has served as an advisor to GlaxoSmithKline and Deerfield Capital. DP has served as an advisory board, and has received travel/research grants, speaking and teaching fees for Macopharma, Ortho Clinical Diagnostics, Grifols, Terumo, Immucor, Diamed, and Diatech Pharmacogenetics. THK has served an advisor to Novartis, Gilead, Intercept and Engitix. LV declares following potential conflicts of interests; speaking fees: MSD, Gilead, AlfaSigma, AbbVie, Consulting: Gilead, Pfizer, Astra Zeneca, Novo Nordisk, Intercept pharmaceuticals, Diatech Pharmacogenetics, IONIS; Research grants: Gilead. All other authors declare that there are no conflicts of interest.
Funding Statement
AG has received support by NordForsk Nordic Trial Alliance (NTA) grant, by Academy of Finland Fellow grant N. 323116 and the Academy of Finland for PREDICT consortium N. 340541. The Richards research group is supported by the Canadian Institutes of Health Research (CIHR) (365825 and 409511), the Lady Davis Institute of the Jewish General Hospital, the Canadian Foundation for Innovation (CFI), the NIH Foundation, Cancer Research UK, Genome Quebec, the Public Health Agency of Canada, the McGill Interdisciplinary Initiative in Infection and Immunity and the Fonds de Recherche Quebec Sante (FRQS). TN is supported by a research fellowship of the Japan Society for the Promotion of Science for Young Scientists. GBL is supported by a CIHR scholarship and a joint FRQS and Quebec Ministry of Health and Social Services scholarship. JBR is supported by an FRQS Clinical Research Scholarship. Support from Calcul Quebec and Compute Canada is acknowledged. TwinsUK is funded by the Welcome Trust, the Medical Research Council, the European Union, the National Institute for Health Research-funded BioResource and the Clinical Research Facility and Biomedical Research Centre based at Guy's and St. Thomas' NHS Foundation Trust in partnership with King's College London. The Biobanque Quebec COVID19 is funded by FRQS, Genome Quebec and the Public Health Agency of Canada, the McGill Interdisciplinary Initiative in Infection and Immunity and the Fonds de Recherche Quebec Sante. These funding agencies had no role in the design, implementation or interpretation of this study. The COVID19-Host(a)ge study received infrastructure support from the DFG Cluster of Excellence 2167 Precision Medicine in Chronic Inflammation (PMI) (DFG Grant: EXC2167). The COVID19-Host(a)ge study was supported by the German Federal Ministry of Education and Research (BMBF) within the framework of the Computational Life Sciences funding concept (CompLS grant 031L0165). Genotyping in COVID19-Host(a)ge was supported by a philantropic donation from Stein Erik Hagen. The COVID GWAs, Premed COVID-19 study (COVID19-Host(a)ge_3) was supported by Grupo de Trabajo en Medicina Personalizada contra el COVID-19 de Andalucia and also by the Instituto de Salud Carlos III (CIBERehd and CIBERER). Funding comes from COVID-19-GWAS, COVID-PREMED initiatives. Both of them are supported by Consejeria de Salud y Familias of the Andalusian Government. DMM is currently funded by the the Andalussian government (Proyectos Estrategicos-Fondos Feder PE-0451-2018). The Columbia University Biobank was supported by Columbia University and the National Center for Advancing Translational Sciences, NIH, through Grant Number UL1TR001873. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or Columbia University. The SPGRX study was supported by the Consejeria de Economia, Conocimiento, Empresas y Universidad #CV20-10150. The GEN-COVID study was funded by: the MIUR grant Dipartimenti di Eccellenza 2018-2020 to the Department of Medical Biotechnologies University of Siena, Italy; the Intesa San Paolo 2020 charity fund dedicated to the project NB/2020/0119; and philanthropic donations to the Department of Medical Biotechnologies, University of Siena for the COVID-19 host genetics research project (D.L n.18 of March 17, 2020). Part of this research project is also funded by Tuscany Region Bando Ricerca COVID-19 Toscana grant to the Azienda Ospedaliero Universitaria Senese (CUP I49C20000280002). Authors are grateful to: the CINECA consortium for providing computational resources; the Network for Italian Genomes (NIG) (http://www.nig.cineca.it) for its support; the COVID-19 Host Genetics Initiative (https://www.covid19hg.org/); the Genetic Biobank of Siena, member of BBMRI-IT, Telethon Network of Genetic Biobanks (project no. GTB18001), EuroBioBank, and RD-Connect, for managing specimens. Genetics against coronavirus (GENIUS), Humanitas University (COVID19-Host(a)ge_4) was supported by Ricerca Corrente (Italian Ministry of Health), intramural funding (Fondazione Humanitas per la Ricerca). The generous contribution of Banca Intesa San Paolo and of the Dolce&Gabbana Fashion Firm is gratefully acknowledged. Data acquisition and sample processing was supported by COVID-19 Biobank, Fondazione IRCCS Ca Granda Milano; LV group was supported by MyFirst Grant AIRC n.16888, Ricerca Finalizzata Ministero della Salute RF-2016-02364358, Ricerca corrente Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, the European Union (EU) Programme Horizon 2020 (under grant agreement No. 777377) for the project LITMUS- Liver Investigation: Testing Marker Utility in Steatohepatitis, Programme Photonics under grant agreement 101016726 for the project REVEAL: Neuronal microscopy for cell behavioural examination and manipulation, Fondazione Patrimonio Ca' Granda Liver Bible PR-0361. DP was supported by Ricerca corrente Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, CV PREVITAL Strategie di prevenzione primaria nella popolazione Italiana Ministero della Salute, and Associazione Italiana per la Prevenzione dell'Epatite Virale (COPEV). Genetic modifiers for COVID-19 related illness (BeLCovid_1) was supported by the Fonds Erasme. The Host genetics and immune response in SARS-Cov-2 infection (BelCovid_2) study was supported by grants from Fondation Leon Fredericq and from Fonds de la Recherche Scientifique (FNRS). The INMUNGEN-CoV2 study was funded by the Consejo Superior de Investigaciones Cientificas. KUL is supported by the German Research Foundation (LU 1944/3-1) SweCovid is funded by the SciLifeLab/KAW national COVID-19 research program project grant to Michael Hultstrom (KAW 2020.0182) and the Swedish Research Council to Robert Frithiof (2014-02569 and 2014-07606). HZ is supported by Jeansson Stiftelser, Magnus Bergvalls Stiftelse. The COMRI cohort is funded by Technical University of Munich, Munich, Germany. Genotyping for the COMRI cohort was performed and funded by the Genotyping Laboratory of Institute for Molecular Medicine Finland FIMM Technology Centre, University of Helsinki, Helsinki, Finland. These funding agencies had no role in the design, implementation or interpretation of this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All institutions contributing cohorts to the COVID-19 Host Genetics Initiative received ethics approval from their respective research ethics review boards. Genetic modifiers for COVID-19 related illness (BelCovid_1) was approved by the Erasme Ethics committee (protocol P2020_209). Host genetics and immune response in SARS-Cov-2 infection (BelCovid_2) was approved by the ethics committee of Liege University Hospital (approval number 2020-242). The BoSCO study was approved by Ethics Committee of the Medical Faculty of the University of Bonn. BQC19 received ethical approval from the JGH research ethics board (2020-2137). The BRACOVID study has been approved by the Hospital das Clinicas, Sao Paulo University Medical School and by Brazilian National IRB, CONEP. COMRI and the COVID-19 biobank of the Faculty of Medicine at Technical University Munich received ethical approval from the local research ethics board (TUM 217/20, TUM 221/20S, TUM 440/20S). San Sebastian Hospital and Basque Biobank (COVID19-Host(a)ge_1) was approved by the Euskadi Ethics Committee on April 6, 2020 (approval number PI2020064). The study in Hospital Universitario Valle Hebron and CIberehd del Instituto Carlos III. Barcelona (COVID19-Host(a)ge_2) was approved by Vall d'Hebron Ethical Committee. COVID GWAs, Premed COVID-19 (COVID19-Host(a)ge_3) was approved by COVID GWAs (ethics id: 0886-N-20) and Premed Covid (ethics id: 1954-N-20). Genetics against coronavirus (GENIUS), Humanitas University (COVID19-Host(a)ge_4) was approved by the ethic committee (approval number reference number 316/20). FoGS was approved by the ethics committee (approval number 342_2020). The GEN-COVID is a multicentre academic observational study was approved by the IRB of each participating centre. The INMUNGEN-CoV2 study was reviewed and approved by the Ethical Committee of the Hospital Clinic of Barcelona (CEIm number: Reg.HCB/2020/0357). NorCoV2 was approved by the Regional Committee for Medical and Health Research Ethics in South-Eastern Norway (project no. 132550). SPGRX was reviewed and approved by the Valladolid Ethics Committee (PI-201716) and the Granada Ethics Committee (no number given) on March 24th, 2020 and April 13th, 2020, respectively. SweCovid was approved by the National Ethical Review Agency (EPM; 2020-01623). UK Biobank was approved by the Northwest Multi-Centre Research Ethics Committee and informed consent was obtained from all participants prior to participation. This study was conducted under project ID 27449. FinnGen was approved by HUS coordinating Ethics committee. The Columbia University Biobank was approved by the Columbia University IRB.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The harmonized individual-level data of some participating cohorts from Belgium (BeLCovid_2), Brazil (BRACOVID), Italy (COVID19-Host(a)ge_4, GEN-COVID), Spain (COVID19-Host(a)ge_1,2,3, INMUNGEN-CoV2, SPGRX), and Sweden (SweCovid) is under preparation to be deposited at the European Genome-phenome Archive (EGA). Regarding the data from genetic modifiers for COVID-19 related illness (BelCovid_1), individual level data were acquired and shared with FIMM during the sanitary crisis under an emergency consent and an ethical approval which were specific to this particular project and do not cover deposition to public repositories. Upon contact with Francoise Wilkin (Francoise.Wilkin{at}erasme.ulb.ac.be), Isabelle Migeotte (Isabelle.Migeotte{at}erasme.ulb.ac.be), or Guillaume Smits (Guillaume.Smits{at}erasme.ulb.ac.be), an institutional data transfer agreement can be established and data shared if the aims of data use are covered by ethical approval and patient consent. The procedure will involve an update to the ethical approval, as well as review by legal departments at both institutions and the process will typically take 2-4 months from initial contact. Regarding the BoSCO study, individual-level genotype and clinical data for purpose of this study were shared with FIMM under a legal, bilateral agreement and were specific to this particular project. Current participant consents and privacy regulations prohibit deposition of individual level data to public repositories. Upon contact with Kerstin Ludwig (kerstin.ludwig{at}uni-bonn.de) or Markus M. Nothen (markus.noethen{at}uni-bonn.de), an institutional data transfer agreement can be established and data shared if the aims of data use is covered by ethical approvals and patient consent. The procedure will involve review by legal departments at both institutions and the process will typically take about 2 months from initial contact. The BQC19 is an Open Science biobank. Instructions on how to access data for individuals from the BQC19 at the Jewish General Hospital site are available here: https://www.mcgill.ca/genepi/mcg-covid-19-biobank. Instructions on how to access data from other sites of the BQC19 are available here: https://www.bqc19.ca/en/access-data-samples. For the COMRI cohort, data protection legislation does not allow for deposition of individual level data in public repositories. Upon direct contact with Prof Ulrike Protzer (protzer{at}tum.de, genetic data) and Dr Christoph Spinner (christoph.spinner{at}tum.de), an institutional data transfer agreement can be established and data will be shared if the aims of data use are covered by ethical approvals and patient consent. The procedure will involve an update to the ethical approval as well as review by legal departments at both institutions and the process will typically take 2-3 months from initial contact. Regarding the Fondazione IRCCS Milan data (FOGS study), institutional data privacy regulations prohibit deposition of individual level data to public repositories without a specific consent. Participant written consent also does not cover public sharing of data for use for unknown purposes. Upon contact with professor Luca Valenti (luca.valenti{at}unimi.it) an institutional data transfer agreement can be established and data shared if the aims of data use are covered by ethical approvals and patient consent. The procedure will involve the request for an amendment to the ethical approvals, as well as review by legal departments at both institutions and the process will typically take 1-2 months from initial contact. Regarding Norwegian data (NorCoV2), institutional data privacy regulations prohibit deposition of individual level data to public repositories. Participant written consent also does not cover public sharing of data for use for unknown purposes. Upon contact with professor Tom H Karlsen (t.h.karlsen{at}medisin.uio.no) or professor Johannes R. Hov (j.e.r.hov{at}medisin.uio.no) an institutional data transfer agreement can be established and data shared if the aims of data use is covered by ethical approvals and patient consent. The procedure will involve an update to the ethical approvals, as well as review by legal departments at both institutions and the process will typically take 1-2 months from initial contact. The genetic and phenotype datasets from UK Biobank are available via the UK Biobank data access process (see http://www.ukbiobank.ac.uk/register-apply/).
